Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Brief Description  
To determine if paclitaxel plus AMG 386 is superior to paclitaxel plus placebo as measured by progression-free survival. Subjects will receive weekly paclitaxel + AMG 386/placebo weekly IV until unacceptable side effects or disease progression.
Who may be Eligible  

Key Inclusion criteria:

  • Histologically or cytologically documented invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Radiographically documented disease progression either on or following the last dose of prior chemotherapy regimen for epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Subjects must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound.
  • Up to 3 prior chemotherapy regimens are allowed

Key Exclusion criteria:

  • Subjects with platinum-free interval (PFI) > 12 months from their last platinum-based therapy
  • History of central nervous system metastasis
  • Clinically significant cardiovascular disease within 12 months prior to randomization
  • Subjects with prinary platinum-refractory disease
IRB Number  
Principal Investigator  
Hall, James

For More Information, Contact  Sarah  , Norek
Phone:  (704) 355-1520  Fax:  (704) 355-9897  
Email:  Sarah.Norek@carolinashealthcare.org
Address:Blumenthal Cancer Center 1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204